Development of a N-Acetyl-β-D-glucosaminidase (NAG) Assay on a Centrifugal Lab-on-a-compact-disc (Lab-CD) Platform

DOI PDF Web Site Web Site Web Site ほか1件をすべて表示 一部だけ表示 被引用文献3件 参考文献35件
  • TANAKA Yoshihide
    Health Research Institute, National Institute of Advanced Industrial Science and Technology (AIST)
  • OKUDA Seira
    Faculty of Pharmaceutical Sciences, Kinki University
  • SAWAI Ayumi
    Faculty of Pharmaceutical Sciences, Kinki University
  • SUZUKI Shigeo
    Faculty of Pharmaceutical Sciences, Kinki University

書誌事項

タイトル別名
  • Development of a N-Acetyl-.BETA.-D-glucosaminidase (NAG) Assay on a Centrifugal Lab-on-a-compact-disc (Lab-CD) Platform

この論文をさがす

抄録

A centrifugal microfluidic platform, which is also known as lab-on-a-compact-disc (Lab-CD), was developed for use as a urinary N-acetyl-β-D-glucosaminidase (NAG) activity assay. In this work, Lab-CD design, centrifugal operations and analytical procedures were established. Automated liquid handling on Lab-CD processes, such as fluid transport, sample metering, mixing, and fluorescence detection are accomplished using a portable Lab-CD system. The linearity of the NAG assay using 4-methylumbelliferyl-N-acetyl-β-D-glucosaminide (4-MU-GlcNAc) was found to be acceptable in the range of 2.5 to 20 U L−1; the relative standard deviations for the fluorescence intensity of eight samples (7.5 U L−1) was 6.4%. Clinical diagnostics is one of the most promising applications for Lab-CD technologies. All the benefits of miniaturization, such as reduced sample requirement, reduced reagent consumption and automation, are realized in this investigation.

収録刊行物

被引用文献 (3)*注記

もっと見る

参考文献 (35)*注記

もっと見る

関連プロジェクト

もっと見る

キーワード

詳細情報 詳細情報について

問題の指摘

ページトップへ